Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

C. Warren Olanow

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


A disease-modifying therapy is the most important unmet medical need in the treatment of Parkinson disease (PD). Laboratory studies have identified many promising candidate agents, but none has been proven to be neuroprotective in PD. A major limitation has been the development of an endpoint that accurately reflects the underlying disease state. This dramatically limits the potential for a new drug being approved as a disease-modifying agent in PD. For the present, the best opportunity to provide patients with PD with a disease-modifying effect is with agents that have been approved for their symptomatic effects. This article reviews currently available drugs for PD and considers the evidence that they might have neuroprotective effects in PD.

Original languageEnglish
Pages (from-to)S59-S64
Issue number7 SUPPL. 2
StatePublished - 17 Feb 2009


Dive into the research topics of 'Can we achieve neuroprotection with currently available anti-parkinsonian interventions?'. Together they form a unique fingerprint.

Cite this